We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · April 03, 2021

Intravitreal Aflibercept Injection vs Sham in AMD

JAMA ophthalmology

 

Additional Info

JAMA ophthalmology
Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-Risk Eyes: A Randomized Clinical Trial
JAMA Ophthalmol 2021 Mar 18;[EPub Ahead of Print], JS Heier, DM Brown, SP Shah, N Saroj, S Dang, NK Waheed, CC Wykoff, JL Prenner, DS Boyer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading